UAE orders recall of face mask batch over possible contamination

The United Arab Emirates has initiated a recall of a specific batch of face masks due to potential contamination of the materials used in their production. The Emirates Drug Establishment issued the recall for the batch number 20251015, known as the Nin 160 FMB-NML Facemask C G in blue. This mask is three-ply in construction and characterized by its blue hue.

The Dubai Health Authority has also released a directive on Monday, urging healthcare facilities to adhere to the recall. It has been revealed that the masks were manufactured by Ningbo ETDZ Holdings Ltd in China and distributed within the UAE by Globemed Care LLC. The drug regulator announced the recall following a quality complaint.

Subsequent inspections revealed the presence of foreign material or contamination in units originating from the affected batch. Healthcare professionals, hospitals, clinics, and pharmacies are required to cease the sale, supply, distribution, or use of the affected batch immediately. All available stock of the recalled masks must be identified and quarantined, followed by its return to the local supplier or distributor, Globemed Care LLC.

Detailed records of the quantities identified, quarantined, and returned must be maintained. Residents who have purchased the affected product are advised to stop using any packs with the batch number 20251015 and return them to the point of purchase or the supplier. Healthcare providers are obligated to report any product quality complaints or adverse incidents related to the masks through the approved reporting channels of the Emirates Drug Establishment.

Globemed Care LLC has been ordered to retrieve all distributed quantities within the UAE market. Additionally, the distributor must furnish the regulator with comprehensive details regarding quantities imported, distributed, returned, and those still in stock, along with a complete list of UAE distribution outlets. The regulator also encourages individuals to directly report any quality concerns or adverse incidents involving the product to the authority.